Skip to main content
. 2017 Mar 29;114(15):3981–3986. doi: 10.1073/pnas.1609758114

Fig. 6.

Fig. 6.

Targeting BCL6 in glioma. (A) Effect of RI-BPI on GBM cell viability. GBM cells were treated with indicated concentration of either RI-BPI or empty peptide (EP) for 72 h before analysis. OCI-LY3 and SU-DHL-4 cells were used as positive controls. (B and C) Effect of RI-BPI treatment on JM94 cell growth in vivo. Peptides were administrated intraperitoneally (50 mg⋅kg−1⋅day−1 for 4 d). (D) Western blot results showing the effect of RI-BPI (20 µM, 24 h) on BCL6 downstream targets.